Beam Therapeutics (BEAM) Stock
Clinical stage biotech developing precision genetic medicines. Here's the price, business snapshot, and what's worth knowing about Beam Therapeutics in August 2026.
Beam Therapeutics Inc (BEAM) is a clinical-stage biotechnology company developing precision genetic medicines using base editing — a gene-editing approach that alters individual DNA letters without cutting the DNA double helix. With a market capitalisation around $3.02 billion, Beam is primarily research and development-driven: value depends heavily on clinical trial readouts, regulatory reviews and the commercial potential of a still-early pipeline. The company has collaborations and licensing arrangements typical of the sector and relies on capital markets or partners to fund development. Investors should be aware that biotech equities can be volatile and subject to binary outcomes from trial results; revenue is limited while R&D and clinical costs remain high. This makes Beam a higher-risk, potentially higher-reward holding suitable for investors comfortable with long horizons and concentrated biotech exposure. This is educational information, not personalised advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Beam Therapeutics' stock, with a target price of $51.82, indicating strong growth potential.
Financial Health
Beam Therapeutics is performing well with strong revenue and cash flow, indicating solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Precision gene editing
Beam’s base-editing platform aims for targeted DNA changes that could address genetic diseases, though clinical proof of concept remains essential and uncertain.
Clinical catalysts ahead
Upcoming trial readouts and regulatory updates can materially affect valuation, making timing and binary outcomes important for investors to monitor.
Long-term potential
If successful, therapies may address unmet needs and create durable value, but development is costly and outcomes are not guaranteed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
